Akcea Therapeutics (AKCA) Stock Rating Upgraded by BidaskClub

Akcea Therapeutics (NASDAQ:AKCA) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.

A number of other brokerages also recently weighed in on AKCA. Zacks Investment Research upgraded Akcea Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 19th. Wells Fargo restated a “market perform” rating and issued a $20.00 target price on shares of Akcea Therapeutics in a research note on Monday, March 19th. Stifel Nicolaus upped their price objective on Akcea Therapeutics from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, March 16th. BMO Capital Markets upped their price objective on Akcea Therapeutics from $25.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 27th. Finally, Cowen downgraded Akcea Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $24.75.

How to Become a New Pot Stock Millionaire

Akcea Therapeutics stock opened at $32.00 on Thursday. Akcea Therapeutics has a 12 month low of $8.10 and a 12 month high of $33.99.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AKCA. Nationwide Fund Advisors bought a new position in Akcea Therapeutics in the third quarter valued at $209,000. New York State Common Retirement Fund purchased a new stake in shares of Akcea Therapeutics during the third quarter worth about $810,000. Rhumbline Advisers purchased a new stake in shares of Akcea Therapeutics during the third quarter worth about $353,000. Bank of New York Mellon Corp purchased a new stake in shares of Akcea Therapeutics during the third quarter worth about $1,413,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Akcea Therapeutics in the third quarter worth about $180,000. 29.14% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Akcea Therapeutics (AKCA) Stock Rating Upgraded by BidaskClub” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3296579/akcea-therapeutics-akca-stock-rating-upgraded-by-bidaskclub.html.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Antero Resources  Given a $22.00 Price Target at Jefferies Group
Antero Resources Given a $22.00 Price Target at Jefferies Group
Royal Bank of Canada Reiterates $43.00 Price Target for Masco
Royal Bank of Canada Reiterates $43.00 Price Target for Masco
Harvest Capital Credit  Major Shareholder Jmp Group Llc Buys 1,901 Shares of Stock
Harvest Capital Credit Major Shareholder Jmp Group Llc Buys 1,901 Shares of Stock
Landmark Bancorp  Insider Patrick L. Alexander Sells 400 Shares
Landmark Bancorp Insider Patrick L. Alexander Sells 400 Shares
Sapiens International  Stock Rating Upgraded by Zacks Investment Research
Sapiens International Stock Rating Upgraded by Zacks Investment Research
Q2 2018 Earnings Estimate for Amgen Issued By William Blair
Q2 2018 Earnings Estimate for Amgen Issued By William Blair


© 2006-2018 Ticker Report. Google+.